Respiratory disease testing market driven by growing prevalence of COPD and asthma

Posted On Apr, 26, 2017

Respiratory disease includes all aliments related to upper respiratory tract that plays an important role in exchange of gases. These diseases also include range of infectious diseases such as pneumonia, Tuberculosis (TB), asthma, pulmonary embolism, lung cancer, etc. Production of hazardous gases & lung irritants due to rapid industrialization resulting in growing air pollution is contributing to rising prevalence of respiratory diseases.

As per World Health Organization (WHO), Chronic Obstructive Pulmonary Disorders (COPD) is a progressive life-threatening lung disease that causes emphysema, chronic bronchitis, refractory (nonreversible) asthma, and breathlessness. It is estimated by the WHO that about 3 million deaths were caused by COPD and related diseases in 2015. In addition, around 8.7 million people develop TB across the globe and 50 million struggle with occupational lung diseases annually. Hence, early detection and diagnosis of these diseases is important for on-time treatment to prevent further complications.

The market includes imaging tests, respiratory measurement devices, blood gas tests, and other respiratory tests. Imaging tests such as x-rays, computational tomography scans, etc., are used to detect damage to the lungs caused by emphysema, chronic bronchitis, and nonreversible asthma. These imaging tests account for the largest share of the market due to their widespread adoption as first-line diagnostic tests. With rapid technological advancements, respiratory measurement devices segment is expected to grow over the forecast period. These devices include pulse oximeter, capnographs, ventilators, and peak flow meters, which are used for measuring lung volume and detecting problems associated to lung functioning.

Hospitals, physician clinics, clinical laboratories, and other home care facilities are the end-users of respiratory disease testing. Hospitals account for the largest market share. Hospital infrastructure is well supportive of diagnostic equipment installation & maintenance and provides quick real-time imaging in case of emergencies. Furthermore, physicians prefer in-house testing of patients rather than referring them to third party laboratories. Thus, this segment is expected to continue growing over the forecast period.

North America holds the largest market share across the globe. Growing prevalence of respiratory diseases such as COPD, asthma is the prime reason for dominance of North American countries in the market. Furthermore, rising adoption of portable devices, such as advanced spirometers and noninvasive ventilators, is creating demand for testing devices in North America.

The major players competing in this market include, but are not limited to, Becton Dickinson (Carefusion Corporation); Koninklijke Philips N.V.(Respironics); ResMed Company; Fischer & Paykel; Medtronic; MGC Diagnostics Corporation and Subsidiaries; and CAREstream Medical Ltd. These players hold major position in the market as they own wide product portfolios.

  In-depth report on global respiratory disease testing/diagnostics market by Grand View Research:

http://www.grandviewresearch.com/industry-analysis/respiratory-disease-testing-market

To schedule a free market intelligence database demo, please complete the form below:

This website is secure and your personal details are safe. Privacy policy

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Custom research service

    Custom research service

    Speak to the report author to design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service excellence represented in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • BOA